H1 raises $40M from CVS Health Ventures
What's the deal? H1, an AI-powered platform that helps connect patients with the right doctors, has received a $40M investment in a round led by CVS HealthDealroom has a profile for this one. Try Dealroom → Ventures . The deal deepens an existing partnership between the two companies, which have already collaborated on an AI model that improved the accuracy of healthcare provider directories.
H1's core product is its "Doctor Graph" — a structured map of physician identity, expertise, relationships, and behavioural signals built on one of the world's largest datasets of healthcare professionals. The company says 85% of the top 20 pharma companies and nine out of 10 of the top health plans are customers.
"Making an impact on hundreds of millions of Americans every day is exactly why we started H1," said Ariel Katz, co-founder and chief executive officer.
Why now? The investment comes as H1 says it is profitable and on track to operate as an "above Rule of 40" company in 2026 — a benchmark that measures the combined growth rate and profit margin of a software business. That financial profile makes it an attractive bet for CVS Health Ventures, which backs growth-stage companies focused on making healthcare more accessible and affordable.
The round also follows the pair's joint work on AI-driven provider directory accuracy, a persistent pain point in US healthcare where outdated or incorrect listings delay patient access to care.
What could go wrong? Corporate venture deals can come with strategic strings attached. H1's growing reliance on CVS Health as both investor and partner could complicate relationships with competing health plans or pharmacy benefit managers. The healthcare AI space is also increasingly crowded, with large tech firms and well-funded startups vying to organise provider data.
The signal: H1's classification as a late-growth-stage company on Dealroom, combined with its claim of profitability and above-Rule-of-40 performance, places it in a relatively rare category: a healthtech startup that has already crossed the commercial traction threshold most AI-driven data platforms struggle to reach. CVS Health Ventures backing a company at this maturity level — rather than an early-stage bet — suggests that the corporate VC arm is prioritising near-term, deployable infrastructure over speculative R&D, a pattern that may accelerate consolidation around a handful of dominant provider-data platforms.
Read more: GlobeNewswire
